Cargando…
Therapeutic approaches to slowing the progression of diabetic nephropathy – is less best?
OBJECTIVE: Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors are known to reduce proteinuria and have been the first-line agents in the management of diabetic nephropathy for the past 20 years. This review covers recent studies that compare the benefit of add...
Autores principales: | Vivian, Eva, Mannebach, Chelsea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Just Medical Media Limited
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884747/ https://www.ncbi.nlm.nih.gov/pubmed/24432038 http://dx.doi.org/10.7573/dic.212249 |
Ejemplares similares
-
Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy
por: Rayego-Mateos, Sandra, et al.
Publicado: (2020) -
Therapeutic Advances in Diabetic Nephropathy
por: Sawaf, Hanny, et al.
Publicado: (2022) -
Mesenchymal Stem Cells as Therapeutic Candidates for Halting the Progression of Diabetic Nephropathy
por: Paulini, Janaina, et al.
Publicado: (2016) -
Slowing the Progression of Diabetic Kidney Disease
por: Blazek, Olivia, et al.
Publicado: (2023) -
New therapeutic agents in diabetic nephropathy
por: Kim, Yaeni, et al.
Publicado: (2017)